Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Efient

Eli Lilly HQ

Lilly delays filing of Lantus rival on safety concerns

Concerns over changes in liver fat detected in phase III trials

Eli Lilly HQ

Lilly sets back evacetrapib data deadline

Cholesterol drug trials extended by six months

- PMLiVE

England’s medicine prices ‘too high’

New analysis finds NICE is too lenient on pharma’s price tags

National Institute for Health and Care Excellence NICE logo

NICE sets out approach to stop antimicrobial resistance

Guidelines call for formation of stewardship programmes

- PMLiVE

NICE issues fresh rejection for Celgene’s cancer drug Imnovid

Drugpricing watchdog says the treatment is too costly for NHS use

- PMLiVE

Co-operative Pharmacy rebrands as Well

Work carried out by advertising agency Langland

- PMLiVE

Lilly and Boehringer claim first place for diabetes combination

US FDA backs Glyxambi as first combination of SGLT2 inhibitor and DPP-4 inhibitor.

UK flag

No further price cut for non-PPRS drugs in UK

But industry concerned over long-term plan for statutory medicines on the NHS

Eli Lilly HQ

Lilly eyes pivotal trials for pain drug tanezumab in 2015

Drug was placed under clinical hold by FDA in 2010

- PMLiVE

NICE consults on reducing melanoma cases

New guidance set to focus on diagnosing and managing the skin cancer  

- PMLiVE

NICE backs first ‘ultra-orphan’ drug Soliris

Final guidance backs Alexion’s treatment for very rare blood clot condition

- PMLiVE

Boehringer and Lilly sway NICE with new Jardiance data

Diabetes drug now backed to help glycaemic control in adults

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links